{
  "id": 127285,
  "name": "JAZZ PHARMACEUTICALS",
  "slug": "jazz-pharmaceuticals",
  "state": "CA",
  "description": "&#226;€‹Biopharmaceutical company.",
  "totalSpending": 1550000,
  "filings": 27,
  "yearlySpending": [
    {
      "year": 2019,
      "income": 240000
    },
    {
      "year": 2020,
      "income": 240000
    },
    {
      "year": 2021,
      "income": 240000
    },
    {
      "year": 2022,
      "income": 240000
    },
    {
      "year": 2023,
      "income": 240000
    },
    {
      "year": 2024,
      "income": 150000
    },
    {
      "year": 2025,
      "income": 200000
    }
  ],
  "firms": [
    "TIBER CREEK GROUP"
  ],
  "lobbyists": [
    "SEAN RICHARDSON",
    "JONATHON JONES",
    "JOHN GONZALEZ",
    "ANDREW MCKECHNIE",
    "TIMOTHY MOLINO",
    "JAMES HEIMBACH",
    "MATTHEW LEFFINGWELL",
    "EMILY KIRLIN"
  ],
  "issues": [
    "HCR",
    "BUD",
    "MED",
    null
  ],
  "sampleDescriptions": [
    "Issues related to the Food and Drug Administration and appropriations.",
    "Issues related to the FDA and the STATES Act (S. 3032)",
    "Appropriations issues related to the FDA and CBD products",
    "Appropriations issues related to the FDA CBD products, HHS pertaining to CBD policy.",
    "Issues related to the FDA STATES Act (S. 3032), and Health and Human Services pertaining to CBD policies.",
    "Issues related to the FDA and the STATES Act (S. 3032), HHS pertaining to CBD policy.",
    "Appropriations issues related to the FDA CBD products, HHS pertaining to CBD policy. Fiscal Year 2021 Labor/HHS Education funding bill",
    "Appropriations issues related to the FDA CBD products, HHS pertaining to CBD policy. Fiscal Year 2021 Labor/HHS Education funding bill (H.R. 7614), Ag/FDA Appropriations (H.R. 7610), Commerce, Justice, Science Appropriations (H.R. 7667)",
    "Appropriations issues related to the FDA CBD products, HHS pertaining to CBD policy. Fiscal Year 2021 Labor/HHS Education funding bill (H.R. 7614), Ag/FDA Appropriations (H.R. 7610), Commerce, Justice, Science Appropriations (H.R. 7667). H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act",
    "Issues related to S. 3032 - the FDA STATES Act, and Health and Human Services pertaining to CBD policies.",
    "Appropriations issues related to the FDA enforcement of non-FDA approved CBD products; FY 2022 Agriculture, Food and Drug Administration Appropriations.",
    "Issues related to the FDA and S. 3032 - the FDA STATES Act, and Health and Human Services pertaining to CBD policies.",
    "Issues related to the FDA and S. 3032 - the FDA STATES Act (115th Congress), and Health and Human Services pertaining to CBD policies.",
    "Appropriations issues related H.R. 4356 - the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act of 2022, pertaining to FDA enforcement of non-FDA approved CBD products.",
    "Appropriations issues related H.R. 4356/S. 2599 - the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act of 2022, pertaining to FDA enforcement of non-FDA approved CBD products.",
    "Appropriations issues related to Senate Amendment to H.R. 2471 - the Consolidated Appropriations Act of FY 2022 - pertaining to FDA enforcement of non-FDA approved CBD products.",
    "Appropriations issues related to the House Ag/ FDA Appropriations bill pertaining to FDA enforcement of non-FDA approved, cannabis derived CBD products.",
    "Issues related to cannabis research; S.253 - Cannabidiol and Marihuana Research Expansion Act; issues related to the FDA; issues related to Cannabis research at Health and Human Services.",
    "Issues related to cannabis research; S. 253 Cannabidiol and Marihuana Research Expansion Act; issues related to the FDA; issues related to Cannabis research at Health and Human Services.",
    "Appropriations issues related to House Ag/FDA Appropriations bill pertaining to FDA enforcement of non-FDA approved, cannabis derived CBD products; Consolidated Appropriations Act, 2023 (PL 117-328)."
  ],
  "years": [
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": -17,
  "trajectory": "stable",
  "yearsActive": 7,
  "avgAnnualSpending": 221429,
  "peakYear": 2019,
  "lobbyistCount": 8,
  "firmCount": 1,
  "issueCount": 3,
  "industry": "healthcare"
}